George O. Waring IV, MD, FACS

From the early days of excimer lasers to recent breakthroughs, each innovation has enhanced our ability to provide safe, effective and efficient solutions for patients.

Personalized vision, or mixing and matching of IOLs to achieve optimal results, is a long-established practice.

We now have more than a year’s worth of experience with Vuity, the first pharmaceutical FDA approved for the treatment of age-related blurry vision or presbyopia.

As presbyopia-correcting IOLs continue to evolve, it is exciting to see lens manufacturers find additional ways to improve the optical performance of these lenses.

At the recent American Ophthalmological Society meeting, I had the honor of presenting research on crystalline lens anatomy, including new parameters that can’t be measured with conventional biometry.

AGN-190584 met the FDA’s high bar for safety and efficacy endpoints in the phase 3 GEMINI study.

The first few cases with a new IOL are always exciting.

It is well known that the crystalline lens anatomy changes with age. However, some of its anatomical features have not previously been well characterized due to the difficulty of imaging and measuring lenses in vivo.

Among the many advancements in IOL platforms recently has been the introduction of selective wavelength filtering.

A patient calls your office to make an appointment for a LASIK consultation. She has finally decided to do something about her vision, but she is 55 years old. What do you do?